(+)-cis-4-(2-fluoro-4-(trifluoromethyl)phenyl)-3-methylpiperidine | 1276655-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (+)-cis-4-(2-fluoro-4-(trifluoromethyl)phenyl)-3-methylpiperidine
• 英文别名: (3R,4R)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-3-methylpiperidine
• CAS: 1276655-94-7
• 化学式: C₁₃H₁₅F₄N
• 分子量: 261.262
• InChiKey: DGNVIGNIUXYKNL-WCBMZHEXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-咪唑并[4,5-b]吡啶-2-甲醛盐酸盐 、 (+)-cis-4-(2-fluoro-4-(trifluoromethyl)phenyl)-3-methylpiperidine 在 magnesium sulfate 、 三乙胺 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 生成 (+)-1-methyl-(2-((cis-(R,R)-3-methyl-4-(4-trifluoromethyl-2-fluoro)phenyl)piperidin-1-yl)methyl)-1H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  1-[(1-Methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis

  摘要：

  A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.

  DOI：

  10.1021/jm101414h
• 作为产物：
  描述：

  4-溴-3-甲基吡啶 在 platinum(IV) oxide 、 四(三苯基膦)钯 、 氢气 、 碳酸氢钠 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 、 异丙醇 为溶剂， 生成 (+)-cis-4-(2-fluoro-4-(trifluoromethyl)phenyl)-3-methylpiperidine
  参考文献：
  名称：

  1-[(1-Methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis

  摘要：

  A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.

  DOI：

  10.1021/jm101414h

文献信息

• BENZIMIDAZOLYL COMPOUNDS
  申请人：Efremov Ivan

  公开号：US20080280933A1

  公开（公告）日：2008-11-13

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中化合物的结构如规范中所定义的I式。还披露了相应的制药组合物、治疗方法、合成方法和中间体。
• 1-[(1-Methyl-1<i>H</i>-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis
  作者：Lei Zhang、Michael A. Brodney、John Candler、Angela C. Doran、Allen J. Duplantier、Ivan V. Efremov、Edel Evrard、Kenneth Kraus、Alan H. Ganong、Jessica A. Haas、Ashley N. Hanks、Keith Jenza、John T. Lazzaro、Noha Maklad、Sheryl A. McCarthy、Weimin Qian、Bruce N. Rogers、Melinda D. Rottas、Christopher J. Schmidt、Judith A. Siuciak、F. David Tingley、Andy Q. Zhang

  DOI：10.1021/jm101414h

  日期：2011.3.24

  A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.